Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
51 hedge funds and large institutions have $97.5M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
9% more funds holding
Funds holding: 47 → 51 (+4)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
76% less capital invested
Capital invested by funds: $403M → $97.5M (-$305M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCOMV
Foresite Capital Opportunity Management V
Larkspur,
California
|
+$4.05M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.22M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 4 |
BlackRock
New York
|
+$1.18M |
| 5 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.78M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.09M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.93M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$944K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$887K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$24K | -2,041 | Closed |
|
|
CS
52
Credit Suisse
Zurich,
Switzerland
| – | +$116 | +14 | New |
|
|
CWM
53
Castle Wealth Management
West Palm Beach,
Florida
| – | +$413 | +50 | New |
|
THRX Hedge Fund Activity: Q2 2022 in Review
51 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q2 2022, worth a combined $97.5M — down 76% from $403M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new THRX positions and 2 closed out — a net gain of 5 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Foresite Capital Opportunity Management V, adding an estimated $4.05M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.78M sold.
- 51 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q2 2022, up from 47 in Q1 2022.
- Funds reported $97.5M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 76% quarter-over-quarter.
- 7 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 2 closed out, a net change of +5 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Foresite Capital Opportunity Management V, an estimated $4.05M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Adage Capital Partners, an estimated $8.78M sold.
Based on aggregated 13F filings for Q2 2022.